FebriDx U.S. Rollout and Reimbursement Update
Key points
- Initial reimbursement signals highly encouraging
- Over 90% of submitted claims being paid
- Foundations being built out ahead of the 2026/27 U.S. flu season
Full summary
Lumos Diagnostics Holdings Ltd, a leader in rapid, point-of-care diagnostic technologies, provides an update on the progress of the FebriDx U.S. rollout following the recent FDA CLIA waiver clearance. The company is focused on building commercial foundations for broader adoption ahead of the 2026/27 U.S. flu season. FebriDx is now in routine use across 44 WellStreet urgent care clinics, and eight additional pilot sites with new urgent care operators are progressing favorably. Early reimbursement data shows over 90% of submitted claims being paid, with average payments above the Medicare fee schedule rate of US$41.38 per test, indicating positive reimbursement performance.
Guidance
null
Outlook
null
Summary generated by a large language model. Please interpret with care.